Skip to main content

Table 2 Attrition (/1000patient-months of follow-up) by enrolment characteristics

From: Trends in clinical characteristics and outcomes of Pre-ART care at a large HIV clinic in Nairobi, Kenya: a retrospective cohort study

Enrolment characteristic Numb dead or LTFu Total months in care Attrition (/1000 patientmths of follow-up) (95% CI)
Overall 685 88,126 7.8 (7.2–8.4)
Gender
Female 363 58,886 6.2 (5.5–6.8)
Male 322 29,240 11.0 (9.8–12.2)
Age group
15–19 12 918 13.1 (5.7–20.4)
20–24 86 5191 16.6 (13.1–20.0)
25–34 295 36,680 8.0 (7.1–9.0)
35–44 209 29,531 7.1 (6.1–8.0)
45–54 68 12,454 5.5 (4.2–6.8)
55Plus 15 3352 4.5 (2.2–6.7)
Marital status
Single 230 18,942 12.1 (10.6–13.7)
Married 335 52,154 6.4 (5.7–7.1)
Divorced 43 5393 8.0 (5.6–10.3)
Widowed 39 7934 4.9 (3.4–6.5)
Not documented 38 3703 10.3 (7.0–13.5)
Residency
Rural 65 14,908 4.4 (3.3–5.4)
Urban 553 66,661 8.3 (7.6–9.0)
Not documented 67 6557 10.2 (7.8–12.7)
Point of entry into care
VCT 327 38,075 8.6 (7.7–9.5)
PMTCT 66 17,440 3.8 (2.9–4.7)
TB Clinic 37 9731 3.8 (2.6–5.0)
Inpatient 46 6150 7.5 (5.3–9.6)
Outpatient 12 1061 11.3 (4.9–17.7)
Other facility 11 1049 10.5 (4.3–16.7)
Other source 63 4280 14.7 (11.1–18.3)
Not documented 123 10,340 11.9 (9.8–14.0)
YoEnr vs YoDg
YoEnr ≠ YoDg 59 10,027 5.9 (4.4–7.4)
YoEnr = YoDg 257 45,336 5.7 (5.0–6.4)
YoDg not documented 369 32,763 11.3 (10.1–12.4)
Disease stage (WHO)   
Stage 1–2 354 62,334 5.7 (5.1–6.3)
Stage 3–4 119 24,099 4.9 (4.1–5.8)
Not documented 212 1693 125.2 (109.5–141.0)
CD4 count
0–100 37 6218 6.0 (4.0–7.9)
101–200 28 5561 5.0 (3.2–6.9)
201–250 8 2917 2.7 (0.8–4.6)
251–350 31 9506 3.3 (2.1–4.4)
351–500 85 19,328 4.4 (3.5–5.3)
> 500 216 34,222 6.3 (5.5–7.2)
Not documented 280 10,374 27.0 (23.9–30.1)
TB
No 654 80,707 8.1 (7.5–8.7)
Yes 31 7419 4.2 (2.7–5.6)
PCP
No 662 83,205 8.0 (7.4–8.6)
Yes 23 4921 4.7 (2.8–6.6)
Oral candidiasis
No 673 84,681 7.9 (7.3–8.5)
Yes 12 3445 3.5 (1.5–5.5)
Other OI
No 504 51,738 9.7 (8.9–10.6)
Yes 181 36,388 5.0 (4.3–5.7)
Any OI
No 472 44,453 10.6 (9.7–11.6)
Yes 213 43,673 4.9 (4.2–5.5)
Cryptococcal disease
No 683 87,641 7.8 (7.2–8.4)
Yes 2 485 4.1 (0–9.8)
Oesophageal candidiasis
No 679 87,725 7.7 (7.2–8.3)
Yes 6 401 15.0 (3.1–26.8)
Kaposi’s sarcoma
No 681 87,567 7.8 (7.2–8.4)
Yes 4 559 7.2 (0.2–14.1)
Lymphoma
No 684 88,084 7.8 (7.2–8.3)
Yes 1 42 23.8 (0–69.9)
  1. VCT voluntary counselling and testing; PMTCT prevention of mother to child transmission; TB tuberculosis; PCP pneumocystis carinii pneumonia; OI opportunistic infection